IPR-803: Selective Urokinase Receptor Inhibitor for Tumor Invasion and Metastasis Studies

Executive Summary: IPR-803 is a competitive small molecule inhibitor targeting the urokinase receptor (uPAR), blocking its interaction with urokinase-type plasminogen activator (uPA) and thereby serving as a precise tool for studying tumor invasion and metastasis. The meta-carboxyl group of IPR-803 enables specific binding to uPAR (Arg53), underpinning its activity. In vitro, IPR-803 inhibits uPAR-uPA binding with an IC₅₀ of 10 μM and demonstrates concentration-dependent suppression of tumor cell invasion and angiogenesis in breast and pancreatic cancer models. In vivo, both oral and intravenous formulations prevent lung metastasis and potentiate gemcitabine efficacy in mouse models, without notable systemic toxicity. APExBIO supplies IPR-803 (CAS: 892243-35-5, SKU: BA8331), with full product specifications and application protocols available online (IPR-803 product page).

Biological Rationale

Urokinase-type plasminogen activator receptor (uPAR) is a membrane glycoprotein that localizes proteolytic activity to the cell surface, facilitating pericellular matrix degradation and tumor invasion. The uPAR-uPA interaction is critical for activating plasminogen, leading to extracellular matrix (ECM) remodeling and metastasis. Persistent uPAR signaling is implicated in aggressive tumor behavior, angiogenesis, and resistance to chemotherapy, especially in breast and pancreatic cancers. As a result, compounds that disrupt this axis, such as IPR-803, are of high research value for dissecting metastatic cascades and developing anti-metastatic strategies (Fu et al., 2026).

Mechanism of Action of IPR-803

IPR-803 acts as a competitive uPAR inhibitor, binding specifically to the Arg53 residue via its meta-carboxyl group. This prevents uPA from engaging uPAR, thus inhibiting the subsequent activation of plasminogen and downstream proteolysis. The blockade of the uPAR-uPA interaction reduces pericellular proteolytic activity, impedes tumor cell invasion, and suppresses angiogenic signaling through pathways such as p-ERK. Notably, IPR-803's selectivity allows for targeted modulation of the uPAR-uPA axis without broadly affecting cell adhesion or migration (product information).

Evidence & Benchmarks

• IPR-803 inhibits uPAR-uPA binding in biochemical assays with an IC₅₀ of 10 μM (phosphate-buffered saline, 25°C, 1 h incubation) (product information).
• In vitro, in MDA-MB-231 breast cancer and pancreatic cancer cell lines, IPR-803 at 25–200 μM inhibits tumor cell invasion and downregulates uPA and p-ERK expression (Fu et al., 2026).
• Oral dosing at 200 mg/kg in orthotopic breast cancer lung metastasis mouse models significantly reduces metastatic burden (product information).
• In a pancreatic cancer xenograft model, intravenous administration of IPR-803 (10 mg/kg, in a pH-responsive nanomedicine) loosens tumor stroma, inhibits angiogenesis, and enhances gemcitabine efficacy without systemic toxicity (Fu et al., 2026).
• IPR-803 does not significantly affect cell migration or adhesion, indicating mechanistic selectivity for invasion and angiogenesis pathways (internal article).

This article extends prior discussions of IPR-803 by integrating recent nanomedicine data and clarifying its distinct application limits, as compared to previous summaries of uPAR inhibitor workflows.

Applications, Limits & Misconceptions

IPR-803 is used extensively in translational oncology research as a breast cancer metastasis inhibitor and a pancreatic cancer research compound. Its validated use cases include:

• Dissecting tumor invasion mechanisms in cell-based assays.
• Evaluating anti-angiogenic interventions in vitro and in vivo.
• Remodeling tumor stroma to enhance chemotherapeutic delivery in xenograft models.
• Testing combination therapies with gemcitabine in pancreatic ductal adenocarcinoma studies.

However, IPR-803 is not effective for broad cytotoxicity screening, as it shows limited effects on cell proliferation and does not impair cell migration or adhesion. Its defined activity window (25–200 μM in vitro; 10–200 mg/kg in vivo) should be adhered to for reliable results.

Common Pitfalls or Misconceptions

• Assuming IPR-803 is a general anti-proliferative agent: It primarily inhibits invasion and angiogenesis, not baseline cell growth (product information).
• Using in long-term solution storage: IPR-803 solutions are unstable and should be prepared fresh for each experiment.
• Applying outside validated cancer models: Efficacy is not established in non-carcinoma or non-mammalian systems.
• Confusing uPAR inhibition with direct uPA inhibition: IPR-803 blocks the uPAR-uPA interaction, not uPA enzymatic activity.
• Neglecting the need for specific dosing: Activity is concentration-dependent, and off-target effects may arise at supraphysiological concentrations.

Workflow Integration & Parameters

• In vitro invasion assays: Use 25–200 μM IPR-803 in serum-free medium for 24–48 h; optimal for breast and pancreatic cancer cell lines.
• uPAR-uPA binding inhibition: Preincubate with IPR-803 (10–100 μM) for 1 h at 25°C in PBS before protein interaction readout.
• Angiogenesis assays: Apply 25–200 μM for tube formation or endothelial sprouting studies.
• In vivo oral administration: Dose mice with 200 mg/kg IPR-803 daily; monitor for metastatic burden reduction over 3–4 weeks.
• Nanomedicine formulation (pancreatic cancer): Incorporate 10 mg/kg IPR-803 in pH-responsive nanoparticles; inject intravenously twice weekly.
• Storage: Store solid IPR-803 at –20°C; avoid prolonged storage of solutions.

For extended protocol details and formulation guidance, consult the APExBIO IPR-803 datasheet.

Conclusion & Outlook

IPR-803 is a rigorously benchmarked urokinase receptor inhibitor with selective, concentration-dependent activity against tumor invasion and angiogenesis in breast and pancreatic cancer models. Its role in stroma remodeling and synergy with chemotherapy are substantiated by recent in vivo evidence. The compound offers a robust platform for anti-metastatic research, particularly in settings where uPAR-uPA signaling is a driver of disease progression (Fu et al., 2026). Future applications may include expanded combinatorial regimens and further refinement of targeted delivery systems, contingent on ongoing preclinical validation.